PNTG trades 1.8% above Wall Street's consensus target of $39.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes PNTG achieves its forward estimates and maintains a stable P/E multiple of 29.3x. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, The Pennant Group, Inc. (PNTG) has a Wall Street consensus price target of $39.00, based on estimates from 7 covering analysts. With the stock currently trading at $39.70, this represents a potential downside of -1.8%. The company has a market capitalization of $1.38B.
Analyst price targets range from a low of $38.00 to a high of $40.00, representing a 5% spread in expectations. The median target of $39.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, PNTG trades at a trailing P/E of 47.3x and forward P/E of 29.3x. The forward PEG ratio of 2.92 reflects a premium valuation. Analysts expect EPS to grow +59.5% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $34.76, with bear and bull scenarios of $21.90 and $45.80 respectively. Model confidence stands at 52/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
ADUSAddus HomeCare Corporation | $2.0B | $105.97 | $122.00 | +15.1% | Buy | 15.2x | 16 |
ENSGThe Ensign Group, Inc. | $10.0B | $170.87 | $222.33 | +30.1% | Buy | 22.6x | 13 |
NVSTEnvista Holdings Corp | $4.4B | $27.13 | $28.33 | +4.4% | Hold | 18.9x | 19 |
NHCNational HealthCare Corporation | $3.4B | $216.40 | — | — | — | 27.2x | — |
SGRYSurgery Partners, Inc. | $2.2B | $17.17 | $19.33 | +12.6% | Buy | 40.0x | 22 |
OPCHOption Care Health, Inc. | $3.4B | $21.57 | $31.22 | +44.7% | Buy | 11.7x | 14 |
HCSGHealthcare Services Group, Inc. | $1.7B | $24.39 | $24.50 | +0.5% | Hold | 22.5x | 15 |
AVAHAveanna Healthcare Holdings Inc. | $2.1B | $9.60 | $10.00 | +4.2% | Buy | 16.5x | 12 |
UNHUnitedHealth Group Incorporated | $388.9B | $428.19 | $426.75 | -0.3% | Buy | 23.3x | 52 |
HUMHumana Inc. | $47.4B | $394.62 | $298.50 | -24.4% | Hold | 44.6x | 44 |
Quick answers to the most common questions about buying PNTG stock.
Wall Street's consensus price target for PNTG is $39, -1.8% from its current price of $39.7. The below-market target from 7 analysts suggests limited near-term appreciation.
PNTG has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $39 implies -1.8% downside from current levels.
PNTG trades at a forward P/E of 29.3444x, representing a moderate valuation. With analysts targeting $39 (-1.8% implied move), the stock appears close to fair value.
The most bullish Wall Street analyst has a price target of $40 for PNTG, while the most conservative target is $38. The consensus of $39 represents the median expectation. Our quantitative valuation model projects a bull case target of $46 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
PNTG is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month PNTG stock forecast based on 7 Wall Street analysts shows a consensus price target of $39, with estimates ranging from $38 (bear case) to $40 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $35, with bear/bull scenarios of $22/$46.
Our quantitative valuation model calculates PNTG's fair value at $35 (base case), with a bear case of $22 and bull case of $46. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 52/100.
PNTG trades at a forward P/E ratio of 29.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 47.3x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on PNTG, with 0 Sell ratings and a price target of $39 (-1.8% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
PNTG analyst price targets range from $38 to $40, a 5% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $39 consensus represents the middle ground. Our model's $22-$46 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.